GleamWall
中文EN

DCOY Decoy Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1615219 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-231.0%
TTM EPS YoY118.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-11,102.9%
ROA-222.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets48.3%
Debt / equity0.00x
Current ratio1.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.56x
Accruals ratio-98.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$368,170$770,027
SG&A expense$3.73M$4.96M
Operating income-$12.61M-$5.73M
Income tax$0—
Net income-$12.52M-$5.58M
EBITDA-$12.61M-$5.73M
EPS (basic)-129.10-69.54
EPS (diluted)-129.10-69.54
Weighted avg. shares (diluted)96,96780,184
Balance sheet
Cash & equivalents$10.71M$2.43M
Current assets$10.99M$2.99M
PP&E, net$40,559$0
Total assets$11.06M$3.02M
Current liabilities$5.17M$1.51M
Total liabilities$5.17M$1.51M
Shareholders' equity$5.89M$1.51M
Shares outstanding531,96896,077
Cash flow statement
Operating cash flow-$4.83M-$4.53M
Capital expenditure$577,000$0
Free cash flow-$5.40M-$4.53M
Investing cash flow$764,735$0
Financing cash flow$12.34M$1.06M
Depreciation & amortization$7,151$4,424
Stock-based compensation$219,058$273,730

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.